| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... Nature communications 12 (1), 6896, 2021 | 75 | 2021 |
| Melatonin ameliorates Aβ1-42-induced Alzheimer's cognitive deficits in mouse model YH Gong, N Hua, X Zang, T Huang, L He Journal of Pharmacy and Pharmacology 70 (1), 70-80, 2018 | 42 | 2018 |
| Identification of Piperlongumine (PL) as a new E3 ligase ligand to induce targeted protein degradation J Pei, Y Xiao, X Liu, W Hu, A Sobh, Y Yuan, S Zhou, N Hua, ... biorxiv, 2022.01. 21.474712, 2022 | 35* | 2022 |
| Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition P Pal, D Thummuri, D Lv, X Liu, P Zhang, W Hu, SK Poddar, N Hua, ... Journal of medicinal chemistry 64 (19), 14230-14246, 2021 | 30 | 2021 |
| BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Journal of Hematology & Oncology 15 (1), 23, 2022 | 29 | 2022 |
| The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ1–42-induced cognitive impairment X Zang, ZY Cheng, Y Sun, N Hua, LH Zhu, L He Progress in Neuro-Psychopharmacology and Biological Psychiatry 81, 250-261, 2018 | 17 | 2018 |
| Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun 12: 6896 D Lv, P Pal, X Liu, Y Jia, D Thummuri, P Zhang, W Hu, J Pei, Q Zhang, ... | 9 | 2021 |
| Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung cancer growth without causing on-target toxicities in mice S Khan, P Kellish, N Connis, D Thummuri, J Wiegand, P Zhang, X Zhang, ... Cell Death Discovery 9 (1), 1, 2023 | 8 | 2023 |
| Polyprenols mitigate cognitive dysfunction and neuropathology in the APP/PS1 mouse XX Zhuang, X Zang, GY Zheng, N Hua, Y Sun, YH Hu, L He Phytotherapy research 32 (6), 1098-1107, 2018 | 7 | 2018 |
| Targeting intracellular proteins with cell type-specific functions for cancer immunotherapy ME Carelock, RP Master, MC Kim, Z Jin, L Wang, CK Maharjan, N Hua, ... Life Medicine 2 (3), lnad019, 2023 | 3 | 2023 |
| A BCL-XL PROTAC degrader DT2216 synergizes with KRASG12C inhibitors for effectively treating KRASG12C-mutated cancers S Khan, J Wiegand, P Zhang, W Hu, D Thummuri, V Budamagunta, N Hua, ... Cancer Research 82 (12_Supplement), 5313-5313, 2022 | 1 | 2022 |
